{"filing":{"accession_number":"0001437749-26-020491","cik":"0001001316","ticker":"TGTX","company_name":"TG THERAPEUTICS, INC.","form":"8-K","filing_date":"2026-06-12","report_date":null,"primary_document":"tgtx20260612_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1001316/000143774926020491/tgtx20260612_8k.htm"},"events":[{"id":10300,"run_id":9034,"accession_number":"0001437749-26-020491","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"This is a classic Item 5.07 disclosure reporting the results of TG Therapeutics' 2026 Annual Meeting held on June 11, 2026. The filing presents detailed voting results for three proposals: election of six directors, ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The disclosure is material as it documents shareholder approval of board composition and auditor ratification, though notably Proposal 3 (say-on-pay) was not approved, with 48.9 million votes against versus 31.9 million for.","company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","filing_date":"2026-06-12","form":"8-K","submitted_at":null,"items":[{"id":6586,"accession_number":"0001437749-26-020491","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of TG Therapeutics' 2026 Annual Meeting held on June 11, 2026. The filing presents detailed voting results for three proposals: election of six directors, ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The disclosure is material as it documents shareholder approval of board composition and auditor ratification, though notably Proposal 3 (say-on-pay) was not approved, with 48.9 million votes against versus 31.9 million for.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:01:45.839717+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":6586,"accession_number":"0001437749-26-020491","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure reporting the results of TG Therapeutics' 2026 Annual Meeting held on June 11, 2026. The filing presents detailed voting results for three proposals: election of six directors, ratification of KPMG LLP as independent auditor, and an advisory vote on named executive officer compensation. The disclosure is material as it documents shareholder approval of board composition and auditor ratification, though notably Proposal 3 (say-on-pay) was not approved, with 48.9 million votes against versus 31.9 million for.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-13T00:01:45.839717+00:00","company_name":"TG THERAPEUTICS, INC.","ticker":"TGTX","filing_date":"2026-06-12"}]}